MARY CHAMBERLAIN: Open Payments
NPI 1487112876 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$414 in 18 payments from 8 companies in 2025. Trend: 2023 $24 · 2024 $877 · 2025 $414
Food & beverage: $414
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $129 |
| ABBVIE INC. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Neurocrine BioSciences, Inc. | 2 | $58 |
| E.R. Squibb & Sons, L.L.C. | 1 | $28 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| Alkermes, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: UZEDY, VRAYLAR, TRINTELLIX, INGREZZA, AUSTEDO XR, COBENFY, INVEGA SUSTENNA, ARISTADA.
Industry payments across CO — which companies pay providers there.
